Citric Acid/Lactic Acid/Potassium Bitartrate

— Pharma 1 Will Place Launch Quantity Order for PHEXXI in July 2025 — — Commercial Launch in UAE Targeted for Q1 2026 — SAN DIEGO, June 23, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM) announced today that private Emirati health care company Pharma 1 Drug Store LLC has filed an application with the United Arab Emirates (UAE) Ministry of Health and Prevention (MOHAP) seeking approval to commercialize PHEXXI® (lactic acid, citric acid, and potassium bitartrate) Evofem's FDA-approved hormone-free contraceptive, in the UAE. "With the submission to MOHAP now complete, we are developing our commercial strategy for PHEXXI in the UAE and look forward to launching this important product as quickly as possible following approval," said Abdulwahab Atfah, CEO of Pharma 1 Drug Store. "Market research indicates a growing demand for hormone-free, on demand contraception in the UAE and the surrounding region. We expect PHEXXI will be extremely well received among OB/GYNs and the women they serve." "This filing is an important milestone towards the commercialization of PHEXXI outside the U.S.," said Evofem CEO Saundra Pelletier. "We look forward to expanding and diversifying our revenue stream with PHEXXI sales to Pharma 1 for the UAE beginning in July 2025 to support the product launch in the UAE and provide Emirati women with access to hormone-free, non-systemic birth control that they control and use on-demand, only when needed." Pharma 1 holds the exclusive commercialization rights for PHEXXI in the Middle East, including the UAE, Kuwait, Saudi Arabia, Qatar and certain other countries in the licensed Territory. Pharma 1 is responsible for obtaining and maintaining any regulatory approvals required to market and sell PHEXXI, and will handle all aspects of distribution, sales and marketing, pharmacovigilance and all other commercial functions in these countries. Since its inception in 2019, Pharma 1 has continued to successfully execute its mission of offering practical solutions to fulfill health care needs based on scientific studies and accurate surveys. The company's success reflects its substantial expertise, scientific approach, and agility to adapt to the very dynamic and growing market in the Gulf Cooperation Council (GCC). PHEXXI is the first and only locally-acting contraceptive gel approved by the U.S. Food and Drug Administration (FDA). It is applied zero-to-60 minutes before intercourse using a pre-filled applicator and works, without hormones, by maintaining the normal vaginal microbiome with a pH that is naturally inhospitable to sperm as well as certain viral and bacterial pathogens. About Evofem Biosciences Evofem Biosciences, Inc. is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company generates revenue from the sale of two FDA-approved products: the hormone-free contraceptive PHEXXI® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, and SOLOSEC® (secnidazole) 2 g oral granules, an FDA-approved oral antibiotic indicated for the treatment of bacterial vaginosis (BV) in females 12 years of age and older, and trichomoniasis in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose. Evofem's commercial team relaunched SOLOSEC in November 2024 and promotes the product alongside PHEXXI to OB/GYNs in the U.S. 2024 marked Evofem's fourth consecutive year of net sales growth. Evofem is entering global markets through strategic partnerships, including its license agreements with Pharma 1 Drug Store LLC under which PHEXXI and SOLOSEC are expected to launch in the United Arab Emirates (UAE) in 2026. Learn more at evofem.com. PHEXXI® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc. About Pharma 1 Pharma 1 Drug Store is an Emirati company dedicated to providing practical solutions, backed by scientific studies and accurate surveys, that cater to the ever-evolving healthcare needs of people in the GCC and support development of a healthier community. Pharma 1 are agents to a growing number of pharmaceutical companies, with a variety of commercial products and medications in process with the Ministry of Health and Prevention. Learn more at . Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "anticipate," "aim," "believe," "continue," "could," "expect," "intend," "plan," "possible," "potential," "predict," "project," "seek," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to expected timing of the launch quantity order, regulatory approval of PHEXXI in the UAE, and commercial launch, and the level of demand for PHEXXI in the UAE. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 24, 2025, amended on March 28, 2025, and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law. Contact Amy Raskopf Evofem Biosciences, Inc. [email protected] (917) 673-5775 SOURCE Evofem Biosciences, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

— Pharma 1 Targets Mid-2025 Regulatory Submission in UAE for SOLOSEC to Treat Bacterial Vaginosis and Trichomoniasis — SAN DIEGO, May 21, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM) and private Emirati health care company Pharma 1 Drug Store LLC have signed a License and Supply Agreement for the Middle East rights to SOLOSEC® (secnidazole) 2 g oral granules, Evofem's FDA-approved single-dose oral treatment for two common sexual health conditions. Consideration to Evofem for the exclusive commercial rights to SOLSOEC in the Territory includes an upfront payment, payments on achievement of certain regulatory milestones, and sales-based milestone payments. Once approved, Evofem will supply SOLOSEC to Pharma 1 for sale in the Territory at cost-plus. "SOLOSEC offers a convenient 'one-and-done' oral treatment for two common sexual health conditions, bacterial vaginosis (BV) and trichomoniasis, which affect millions of people in the member states of the Gulf Cooperation Council (GCC)," said Abdulwahab Atfah, CEO of Pharma 1 Drug Store. "We are pleased to secure exclusive commercial rights to SOLOSEC in the Territory and eager to file for regulatory approval of SOLOSEC in the United Arab Emirates (UAE) this summer." "In addition to its strong brand identity, SOLOSEC is manufactured in the United States, which holds considerable value in markets where trust in quality, regulatory rigor, and prescriber confidence are key differentiators," added Mr. Atfah. "We applaud Pharma 1's focus on sexual health, particularly in women, and are excited to expand our strong relationship beyond PHEXXI to now include SOLOSEC," said Evofem CEO Saundra Pelletier. "We are confident that Pharma 1 is the right partner to effectively launch and commercialize SOLOSEC in the UAE and surrounding region." Studies in the Middle East and North Africa (MENA) region have reported BV prevalence ranging from 25% to 41%. A systematic review and meta-analysis of global BV prevalence among reproductive-aged women in the general population found that one in four women in MENA have BV1. In the UAE alone, this represents between 1.0 million and 1.7 million women. Despite the availability of anti-infectives approved to treat Trichomonas vaginalis, the parasite that causes trichomoniasis, in 2020 the WHO estimated 156.3 million new cases of trichomoniasis worldwide: 73.7 million in females and 82.6 million in males.3 Undiagnosed infections and lack of compliance with multi-day treatment regimens are critical contributing factors. A meta-analysis of evidence sourced from 263 international, regional, and national databases found that MENA has a substantial trichomoniasis prevalence, with approximately 4.7% of women in the general population affected by this sexually transmitted infection (STI).2 Trichomoniasis was more common in intermediate- and high-risk populations (17.2% and 10.3%, respectively) and among symptomatic women (13.9%). Under the terms of the agreement, Pharma 1 will have the exclusive commercialization rights for PHEXXI in the Middle East, including the UAE, Kuwait, Saudi Arabia, Qatar and certain other countries in the region. Pharma 1 will be responsible for obtaining and maintaining any regulatory approvals required to market and sell SOLOSEC, and will handle all aspects of distribution, sales and marketing, pharmacovigilance and all other commercial functions in these countries. About Bacterial Vaginosis Bacterial vaginosis (BV), the most common cause of vaginal discharge in reproductive-age women1, is associated with multiple consequential adverse outcomes including an increased risk of adverse birth outcomes, acquisition of human immunodeficiency virus and other STIs, pelvic inflammatory disease, and a high incidence of symptomatic recurrence.4 A study published in the New England Journal of Medicine in 2025 provided evidence that BV is in fact an STI.5 About Trichomoniasis Trichomoniasis (or "Trich") is an STI caused by infection with Trichomonas vaginalis, a protozoan parasite. It is the most common nonviral STI globally, affecting an estimated 156 million men and women worldwide. 3 The CDC notes that up to 70% of people infected with Trich are unaware that they are infected and may unwittingly pass the parasite to sexual partners.6 Untreated infections might last from months to years. In women, Trich can cause a foul-smelling vaginal discharge, genital itching, and pain with urination or sex. Trich is also associated with an increased risk for cervical cancer, infertility, HIV acquisition, and, among women with HIV infection, pelvic inflammatory disease (PID). Pregnant women who have Trich might be at higher risk of delivering their babies prematurely. Men who have Trich typically have no symptoms, however when men do have symptoms these may include itching or irritation inside the penis, burning with urination or after ejaculation and discharge from the penis.2 About SOLOSEC SOLOSEC® (secnidazole) 2 g oral granules is a single dose oral 5-nitroimidazole drug. It is FDA-approved for the treatment of two sexual health diseases: Bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and Trichomonas vaginalis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose. About Evofem Biosciences Evofem Biosciences, Inc. is commercializing two FDA-approved products to address unmet needs in women's sexual and reproductive health: PHEXXI and SOLOSEC. 2024 was its fourth consecutive year of net sales growth. PHEXXI® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc. About Pharma 1 Pharma 1 Drug Store is an Emirati company dedicated to providing practical solutions, backed by scientific studies and accurate surveys, that cater to the ever-evolving healthcare needs of people in the GCC and support development of a healthier community. Pharma 1 are agents to a growing number of pharmaceutical companies, with a variety of commercial products and medications in process with the Ministry of Health and Prevention. Learn more at https://pharma1ds.com/. Sources Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "anticipate," "aim," "believe," "contemplate," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to expected timing of the planned filing for regulatory approval of SOLOSEC in the UAE. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 24, 2025, amended on March 28, 2025, and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law. Contact Amy Raskopf Evofem Biosciences, Inc. araskopf@evofem.com (917) 673-5775 SOURCE Evofem Biosciences, Inc.